An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Table 1 OnabotulinumtoxinA Utilisation

	(N = 633)^a
Treatment sessions per patient
Mean (SD)	5.5 (3.0)
Min, max	1, 13
Patient discontinued onabotulinumtoxinA treatment, n (%)
Follow-up visit 1	27 (4.3)
Follow-up visit 2	43 (6.8)
Follow-up visit 3	30 (4.7)
Follow-up visit 4	21 (3.3)
Follow-up visit 5	11 (1.7)
Follow-up visit 6	7 (1.1)
Follow-up visit 7	3 (0.5)
Follow-up visit 9	1 (0.2)
Follow-up visit 12	1 (0.2)
Patients attending number of treatment sessions, n (%)
≥ 1	633 (100.0)
≥ 2	573 (90.5)
≥ 3	485 (76.6)
≥ 4	420 (66.4)
≥ 5	371 (58.6)
Injection details per session per patient
Mean (SD) total dose, U	155.1 (21.4)
Min, max	13, 208
Mean (SD) muscle areas	6.9 (0.6)
Min, max	3.7, 9.0
Mean (SD) injection sites	31.4 (4.1)
Min, max	13, 63^b
Deviations^c
Dose units, U, n (%)
< 155	232 (36.7)
> 195	33 (5.2)
Injection sites, n (%)
< 31	178 (28.1)
> 39	33 (5.2)
Dosing interval, wk, n (%)
< 11	94 (14.8)
> 13	501 (79.1)
> 13 to ≤16	440 (69.5)
> 16	291 (46.0)

^aPercentages are based on total number of patients who received ≥1 dosage of onabotulinumtoxinA
^bAt the baseline visit (administration visit 1), a maximum of 63 sites per session per patient were injected; across all other administration visits the maximum injection sites per patient was 47
^cA deviation was defined as a change from the recommended injection paradigm: 155 dose units, 31 injection sites, dosing interval between 11 and 13 weeks. A patient with a deviation at any time during the observation period was included in the deviation category; more than 1 reason for a deviation from the recommended treatment paradigm was allowed, and patients were included in as many categories as required to describe any deviations over the entire study duration. Categories are not mutually exclusive

ISSN: 1129-2377